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Abstract: Annona cherimola Mill., or the custard apple, is one of the species belonging to the An-
nonaceae family, is widely used in traditional medicine, and has been reported to be a valuable
source of bioactive compounds. A unique class of secondary metabolites derived from this family
are Annonaceous acetogenins, lipophilic polyketides considered to be amongst the most potent anti-
tumor compounds. This review provides an overview of the chemical diversity, isolation procedures,
bioactivity, modes of application and synthetic derivatives of acetogenins from A. cherimola Mill.
Keywords: Annona cherimola; acetogenins; bioactivity; acetogenin encapsulation; acetogenin formula-
tion; acetogenin drug delivery
1. Introduction
Plants are one of the most important and diverse sources of chemical structures and
bioactive compounds. One of the species that has been used in traditional medicine for
a long time and with a valuable source of bioactive molecules is Annona cherimola Mill.
(ACM) or the custard apple [1]. It belongs to the Annonaceae family, which comprises
more than 140 genera and approximately 2500 species [2]. ACM is an extensively known
deciduous tree whose edible fruit is known as the cherimoya. Cherimoyas are considered
an exotic fruit native to inter-Andean valleys from Peru and Ecuador [3]. They can be
found and are commercially cultivated in several mild-temperature regions around the
world, such as Portugal, Italy, Taiwan or Spain [4]. Around 2406 hectares where mainly
two varieties of this plant are cultivated, ‘Fino de Jete’ and ‘Campa’ [5] can be found in
the coast of Granada-Malaga region (southern of Spain) also known as ‘Costa Tropical’ [6],
which was granted by the European Union a Protected Designation of Origin (PDO) [7] in
2002. In fact, the specific soil and climate conditions as well as the particular requirements
regarding the handling of a crop with a rather brief postharvest life [8] have made of Spain
its world leading producer [2,9]. The commercialization of this cultivar from Coast of
Granada-Malaga around the rest of the European regions has grown by 20% in the last
year [10].
ACM is mainly cultivated for the food industry and although it is often consumed as
fresh fruit in many countries, a varied range of food products and beverages are made up
from cherimoya pulp [11]. In addition to its organoleptic properties and nutritional value,
ACM has a certain potential use in folk medicine, particularly for the treatment of skin
disorders [12]. Additionally, some hepatoprotective, anti-inflammatory and antitumoral
properties have been described [1,2,9]. Over the last few decades, a growing number
of studies have focused on the phytochemical composition of ACM extracts in order to
explain their traditional applications and to determine the compounds in ACM that are
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responsible of its biological activity. Some phytochemicals, such as flavonoids, tocopherols,
tannins, acetogenins, saponins, polyphenols among others, have been isolated from ACM
roots, seeds, pulp and leaves [5,9,13]. Since the first acetogenin, uvaricin was isolated by
Jolad et al. in 1982—a product of interest for its cytotoxic activity—and other investigations
have focused on this class of compounds, which are exclusively found in the Annonaceae
family [14]. Since then, over 500 acetogenins from the Annonaceae family have been
described [15].
Annonaceous Acetogenins (ACGs) are waxy substances formed by derivatives of
long-chain fatty acids where up to three THF rings, sometimes circled by hydroxyl groups,
conform a polar core. Lineal ACGs, or with a central THP ring, double bonds and ketone
groups, have also been described. One lactone ring, at one of the ends of the molecule,
completes the structure up to C37 (Figure 1) [16–19].
Molecules 2021, 26, x FOR PEER REVIEW 2 of 20 
 
 
tumoral properties have been described [1,2,9]. Over the last few decades, a growing 
number of studies have focused on the phytochemical composition of ACM extracts in 
order to explain their traditional applications and to determine the compounds in ACM 
that are responsible of its biological activity. Some phytochemicals, such as flavonoids, 
tocopherols, tannins, acetogenins, saponins, polyphenols among others, have been iso-
lated from ACM roots, seeds, pulp and leaves [5,9,13]. Since the first acetogenin, uvaricin 
was isol ted by Jolad et al. in 1982—a pr duct of interest for its cytot xic activity— and 
other investigations h ve fo used o  this class of compounds, which are exclusiv ly 
ound in the Annonaceae family [14]. Since then, over 500 acetogenins from the An-
nonaceae family have been described [15]. 
ceous cet genins ( s) r        
l  fa ty acids wh re up to three THF rings, sometimes circled by hydroxyl 
groups, conf rm a polar core. Lineal ACGs, or wi h a central THP ring, d uble bonds a d 
ketone groups, hav  also been escribed. O  lactone ring, a  one of the ends of th  
molecul , completes the structure up to C37 (Figure 1) [16–19]. 
 
Figure 1. Overview of annonaceous ACG structure. 
ACGs are currently considered to be amongst the most potent antitumoral com-
pounds [20]. Both in vitro and in vivo cytotoxic activity against a large number of tu-
moral cell lines—some of them resistant to regular therapies—have been studied 
[18,21,22]. These natural products obtained better results than those achieved by more 
conventional treatments. Given these properties, the extraction and purification of its 
individual compounds is a subject of interest. For this purpose, the use of bio-guided 
isolation conducted under chromatographically controlled procedures has been pro-
posed. Such compounds of interest are often found in mixtures where content is scarce, 
which poses a difficulty for structure determination and extraction. The combined use of 
NMR and mass spectrometry is required for a definite identification.  
The number of bioactive compounds and their concentration levels may vary con-
siderably according to the type of cultivar and its origin.  
2. Classification of ACGs from ACM 
The most generally used classification for annonaceous ACGs is based on the 
structure of its systems of central rings. Hence, linear, mono-THF, adjacent or 
non-adjacent bis-THF, tri-THF, epoxy and THP ACGs, could be further divided attend-
ing to the number and location of the hydroxyl groups along the chain, and also accord-
ing to the type of terminal lactone [15,18]. 
Most of the ACGs found in ACM contain one or two THF rings. In addition, a 
number of variations have usually been registered with regard to the number and posi-
tion of the hydroxyl groups. Between one and four hydroxyl groups can be found along 
the aliphatic chain or at the terminal lactone group. Moreover, some of the differences in 
the number and position of the hydroxyl groups, besides their stereochemistry, are cru-
cial for their biological activity. The most common THF and γ-lactone ring structures can 
be seen in Figure 2. This classification has been made following the same criteria as Neske 
and cols. [15]. 
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ACGs are currently considered to be amongst the most potent antitumoral com-
pounds [20]. Both in vitro and in vivo cytotoxic activity against a large number of tumoral
cell lines—some of them resistant to regular therapies—have been studied [18,21,22]. These
natural products obtained better results than those achieved by more conventional treat-
ments. Given these properties, the extraction and purification of its individual compounds
is a subject of interest. For this purpose, the use of bio-guided isolation conducted un-
der chromatographically controlled procedures has been proposed. Such compounds of
interest are often found in mixtures where content is scarce, which poses a difficulty for
structure determination and extraction. The combined use of NMR and mass spectrometry
is required for a definite identification.
The number of bioactive compounds and their concentration levels may vary consid-
erably according to the type of cultivar and its origin.
2. Classification of ACGs from ACM
The most generally used classification for annonaceous ACGs is based on the structure
of its systems of ce tral rings. Hence, linear, mono-THF, adjacent or non-adjacent bis-THF,
tri-THF, epoxy and THP ACGs, could be further divided ttendi g to the numb r and
location of the hydroxyl groups along the chain, and al o according to the type of terminal
lactone [15,18].
Most of the ACGs found in ACM contain one or two THF rings. In addition, a number
of variations have usually been registered with regard to he number and position of the
hydroxyl groups. Between one nd four hydroxyl groups can be f und along the aliphat c
chain or at the terminal lacton group. Moreover, some f the differences in the number
and position of the hydroxyl groups, besides their stereochemistry, are crucial for their
biological activity. The m s common THF and γ-lactone ring ructur s can be s en in
Figure 2. This classifica on has been made following the same criteria as Nesk and
col [15].
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Table 1. Characteristics and structural features of the 41 ACGs described in ACM.












133352-34-8 Corossolin Corossoline 10,15,20 T-A th/t/th L-A C35H64O6 Seeds 15 [23,24]
246165-35-5 Annocherin 4,15,20 T-A th/t/th L-A C35H62O7 Seeds 2 [25]






130853-76-8 Annonacin-A † 4,10,15,20 T-A th/t/er L-A C35H64O7 Seeds 17 [27]
137550-92-6 Annomontacin 4,10,17,22 T-A th/t/th L-A C37H68O7 Seeds 18 [26]
155969-86-1 Xylomaticin 4,10,15,20 T-A th/t/th L-A C37H68O7 Seeds 7 [23]
155969-65-6 Gonionenin (2,4-cis)-Gonioneninone 4,10,13,18 T-A th/t/th L-A C37H66O7 Seeds 8 [23]
176200-77-4 Annosenegalin † 4,10,15,20 T-A th/t/er L-A C37H68O7 Seeds 1 [27]
172586-13-9 Cis annonacin 4,10,15,20 T-A th/c/th L-A C35H64O7 Seeds 10 [28]
344940-10-9 Annocherimolin 4,9,13,18 T-A th/t/th L-A C37H66O7 Seeds 1 [29]
373362-55-1 Annomocherin 4,10,15,20 T-A th/t/th L-A C35H62O7 Seeds 1 [26]
134955-48-9 Gigantetrocin † 4,14,17,18 T-B t/th-th L-A C35H64O7 Seeds 13 [27]


























34-epi 4,15,20,34 T-A th/t/th L-D C35H62O8 Seeds 1 [30]
139294-55-6 Jetein † 10,15,20 T-A th/t/er L-C C35H66O7 Seeds 2 [31]
102989-24-2 Asimicin Squamocin H 4,15,24 T-C th/t/th/t/th L-A C37H66O7 Seeds 57 [32]
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Table 1. Cont.


















4,15,24 T-C th/t/th/t/er L-A C37H66O7 Seeds 229 [31]










Squamocin A 15,24,28 T-C th/t/th/t/er L-A C37H66O7
Seeds,
roots 162 [31,34]





159934-23-3 Squamocin B 13,22,26 T-C th/t/th/t/er L-A C35H62O7 Seeds 10 [32]
123012-00-0 Bullatacinone †
Isorolliniastatin-
2 15,24 T-C th/t/th/t/er L-B1 C37H66O7 Roots 69 [34]
161169-72-8 Isomolvizarin-1 † 13,22 T-C th/t/th/t/er L-B1 C35H62O7 Roots 0 [34]
158252-75-6 Isomolvizarin-2 † 13,22 T-C th/t/th/t/th L-B1 C35H62O7 Roots 1 [34]
125276-75-7 Laherradurin † 15,24,35 T-C th/t/th/t/er L-C C37H68O7 Seeds 13 [35]
139294-54-5 Itrabin † 13,22,33 T-C th/t/th/t/er L-C C35H64O7 Seeds 8 [33]
832683-48-4 Tucumanin 15,24,35 T-C th/t/th/t/th L-C C37H68O7 Seeds 3 [32]
92280-15-4 Otivarin † 16,19,24,35 T-D t/th-th/t/er L-C C37H68O8 Seeds 6 [31]





151637-38-6 Cherimolin-2 † Bullatanocin 4,16,19,24 T-D t/th-th/t/th L-A C37H66O8 Seeds 10 [31]
125620-82-8 Almunequin †
Squamostatin-
A 16,19,24,28 T-D t/th-th/t/er L-A C37H66O8
Seeds,
roots 12 [31,34]
241822-07-1 Aromin-A 15,20 T-D t-th/t/er L-A C35H60O7 Stems 1 [36]
157966-80-8 Isocherimolin-1 † 16,19,24 T-D th-th/t/er L-B1 C37H66O8 Roots 2 [34]
† ACM from the Spanish ‘Tropical Coast’; th = threo; er = erythro; t = trans; c = cis.
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1990 to date, twenty-two ACGs from ACM have b en described. This represents
the main structural group of ACGs isolated from ACM and they hav been mostly found
as mono-THF α,α’-dihydroxylated ACGs (T-A). The most frequent configuration of the
diast reoisom rs is th eo/trans/ hreo. Most of the mono THF acetogenins from ACM
possess a α,β-unsaturated methyl γ-lactone ring (L-A).
2.2. Adjacent Bis-THF Acetogenins
This second structural classification constitutes the next most frequent group.
Thirteen ACGs from ACM have been described as adjacent bis-THF acetogenins. This
bis-THF system is found flanked at the α and α’ positions by two hydroxyl groups
(T-C). Moreover, three types of γ-lactone moiety have been reported, including α,β-
unsaturated methyl γ-lactone (L-A); acetonyl γ-lactone (L-B1) and β-hydroxyl methyl
γ-lactone (L-C) (Table 1 and Figure 3). Nearly all of the ACGs in this class present a
threo/trans/threo/trans/erythro configuration.
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2.3. Non-Adjacent Bis-THF Acetogenins
This constitutes the minor group, with only six ACGs from ACM described until
present; two of them display a hydroxyl group at C4, namely cherimolin-1 and cherimolin-2.
Two types of γ-lactone systems, L-A and L-B1, have been described in this group.
3. Methods Applied for the Purification and Isolation of the ACGs Described in ACM
A wide variety of separation techniques have been successfully used to isolate even
closely related ACG compounds [18]. Most methods comprise a first phase consisting of
the extraction of the dried plant material using methanol, ethanol or dichloromethane as a
solvent. Then, this first step is followed by further fractionations by means of different sep-
arating chromatographic techniques, including open-column chromatography (OPC), flash
chromatography (FC), preparative thin-layer chromatography (PTLC) or high-performance
liquid chromatography (HPLC) [37]. In some cases, the peculiar structure that these nat-
urally occurring compounds present demand the use of rather complex eluent-solvent
mixtures (Table 2).
Moreover, two methods have been used to monitor the fractionation of the ACGs:
brine shrimp lethality test (BST) and Kedde’s reagent [37]. Artemia salina, commonly
known as brine shrimp, is a small crustacean which has been the subject of many studies.
The brine shrimp lethality test is an economic, rapid and reliable tool for the preliminary
assessment of general toxicity [38]. This first method allows the determination of the
most bioactive compounds in a particular extract, and it has rendered good results with
acetogenins [39]. On the other hand, Kedde’s reagent is not specific for ACGs but it allows
the detection of its unsaturated conjugated lactone moiety. This reagent consists of a
solution of 3,5-dinitrobenzoic acid in ethanol (2% w/v) and potassium hydroxide in ethanol
(5.7% w/v) mixed at equal volumes to produce a pink coloration in the sample solution
when α,β-unsaturated γ-lactone moiety is present [39,40].
All in all, methanol is the most often preferred solvent for the extraction of ACGs.
After the extraction, the crude extract is often partitioned using chloroform and water, since
the chloroform layer becomes enriched with the ACGs. Owing to the structural similarities
between the different ACGs, their isolation presents some difficulties. Thus, repeated
open-column chromatography and high-performance liquid chromatography (HPLC) are
often used for their isolation.
Table 2. ACGs isolated from A. cherimola Mill.
Method Eluent System Isolated ACGs Organ Reference
Flash chromatography CH2Cl2-EtOAc-MeOH (4:14:1)
Molvizarin †, motrilin †,
bullatacin †, squamocin †,
cherimolin-1 †, cherimolin-2 †,
almunequin †, itrabin †,
laherradurin †, otivarin †, jetein †
Seeds [31,33]
Flash chromatography CH2Cl2-EtOAc-MeOH (20:19:1)and CH2Cl2-MeOH (24:1)
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Table 2. Cont.
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Molvizarin †, cherimolin-1 †,




† ACM from the Spanish ‘Tropical Coast’. ‡ ACM from California. § ACM from Argentina. # ACM from Taiwan.
4. Biological Activity and Anticarcinogenic Properties of the ACGs Isolated
from ACM
ACGs have recently generated considerable interest because of the wide range of
biological activities that they have exhibited, such as anti-inflammatory, pesticidal, antimi-
crobial and particularly cytotoxic activities. Several studies have already demonstrated
that these compounds present either none or minimal toxicity to normal cells but are highly
toxic to cancerous cells [20,40,41].
ACGs are currently considered to be amongst the most potent antitumoral compounds
and are also effective for the treatment of drug-resistant cancerous cells. It has been well
established that, among other modes of action, this type of compound inhibits the complex
I (NADH-ubiquinone oxidoreductase) found in mitochondrial electron transport systems
as well as glucose uptake (acting as potent modulators of glucose transporters) and also
targets hypoxia-inducible factor-1 (HIF-1). The selectivity of ACGs regarding tumoral cells
could be explained by the higher NADH oxidase content accompanied by the increased
ATP demand that characterize tumoral cells [39,41]. Additionally, several studies have
reported that the ACG’s functional group related to their antineoplastic activity seems to be
their mono or bis-tetrahydrofuran ring accompanied by two or more hydroxyl groups [42].
Thus, the administration of adjacent bis-THF bullatacin, α,β-unsaturated methyl γ-lactone
(L-A) ring at a dose of 15 µg/kg, reduced tumor growth in mice bearing S180 and HepS
xenografts by 65.8% and 63.4%, respectively. These results were superior to those obtained
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using higher concentrations of taxol (40 µg/kg) [43]. Other studies have highlighted the
cytotoxicity of laherradurin, which also possesses an adjacent bis-THF moiety (T-C) and
β-hydroxyl methyl γ-lactone ring (L-C). This ACG has succeeded in reducing the size of
HeLa tumors by similar values to those obtained when doxorubicin (antineoplasic drug)
was employed. Likewise, cherimolin-2, an ACG that contains a non-adjacent bis-THF
moiety (T-D) and a γ-lactone unit (L-A), also reduced the size of tumoral cells, even if it
did not reach laherradurin’s effectiveness [42,44].
Annonacin, which contains a mono-THF α,α’-dihydroxylated system (T-A) and a
α,β-unsaturated methyl γ-lactone ring (L-A), has been one of the most deeply studied
ACGs in the last two decades. This ACG can be found in a large number of species
from the Annonaceae family and good yields can be obtained through isolation processes.
Numerous studies have highlighted the cytotoxicity of this mono-THF ACG. Thus, Yuan
et al. have described that annonacin is able to activate p21 and arrested cancer cells at a
growth-static G1 phase. Furthermore, it presented more significant cytotoxicity to cancer
cells in growth (S phase cells) [45]. Other research by Roduan et al. demonstrated that
the application of annonacin at 85 nM significantly reduced tumor incidence as well as
volume in a two-stage mouse skin tumorigenesis model. Annonacin also appeared to be
non-toxic to liver and kidney, which suggests its potential as a therapeutic compound for
the prevention and treatment of skin cancer [46]. Wang et al. administered 10 mg/kg
of annonacin orally to in vivo hybrid mice (BDF-1) models and successfully inhibit lung
cancer by 57.9% [47].
Moreover, the pesticidal potential of these metabolites has also been reported. For
instance, McLaughlin et al. performed a comparative structure–activity relationship (SAR)
evaluation on the toxicity of 44 ACGs to yellow fever mosquito larvae. Their results
revealed that the compounds bearing adjacent bis-THF rings with three hydroxyl groups
were the most potent ones. Among the ACGs evaluated, bullatacin, with an LC50 value
of 0.1 mg/L, showed the highest activity against yellow fever mosquito larvae. The
compounds with LC50 values below 1.0 mg/L in this assay were considered to be potential
candidates for the development of new pesticides [48].
According to other research studies, ACGs could be involved in the pathogenesis
of certain neurodegenerative disorders, such as in the case of the high prevalence of
atypical parkinsonism that occurs in Guadeloupe, in some parts of the Afro-Caribbean
region and among the Indian population residing in London and New Caledonia. This
could be partially explained by the high consumption of dietary supplements and fruit
products containing plant material from Annonaceae. A study performed by Lannuzel et al.
described that annonacin (extracted from graviola) was toxic to embryonic rat primary
mesencephalic and striatal neurons [49]. Nevertheless, another study carried out by
Potts et al. reported that the toxicity of annonacin was less potent to cortical neurons than
previously reported to mesencephalic and striatal neurons [50]. Champy et al. investigated
the content of annonacin (the major acetogenin) in extracts from fruits and leaves of A.
muricata. It was estimated that a daily consumption of one piece of A. muricata fruit for
one year would result in an aggregate amount of annonacin equivalent to the necessary
dose of the purified compound to be administered by intravenous infusion to induce
brain lesions in rats [51]. However, Awodele and co-workers demonstrated that the
consumption of A. muricata fruit for 60 consecutive days did not induce any significant
toxicity in rat models [52]. This neurotoxicity could also be increased by adding other
metabolites, such as isoquinolinic alkaloids or through the synergic effect with other ACGs.
Although evidence may still remain circumstantial, chronic toxicity as a result of regular
Annonaceae consumption might pose a serious public health issue. Therefore, additional
studies to determine the potential risks of neurodegenerative disorders associated with
chronic exposure due to regular intake of Annonaceae products are needed. It is well
known that any compound can be considered toxic, depending on its dose. It is, therefore,
absolutely crucial to precisely determine the concentration of these metabolites as well
as other chemical constituents in fruit products, infusions, nutritional supplements or
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decoctions made out of plants from the Annonaceae family. Likewise, further research
on the mechanism of action supported by both in vitro and in vivo experiments are also
required. Alternatively, these naturally occurring acetogenins could be modified with the
aim of producing improved derivatives with a lesser toxicity level.
5. How to Apply ACGs from Annona Cherimola Mill.
The acetogenins that can be found in Annona cherimola have been the center of attention
of many researchers because of their cytotoxic effect in different cancer lines [53], as
well as for their tumoral and mitochondrial complex I inhibitory capacities [32,54]. In
addition, these natural products have also exhibited antiparasitic [48], insecticidal [55,56]
and bactericide [57] activity with really promising results.
Despite this wide array of possibilities, the isolation and identification of acetogenins
still represent an obstacle in reaching their practical application. Nevertheless, certain
counter current chromatographic techniques, together with a more recent method based on
absorbent biopolymers, seem to provide more efficient ways to collect acetogenins [58–60].
Thanks to these new isolation methods, a growing number of studies on cell lines, isolated
enzymes and complexes have been completed. Larger scale procedures, however, are still
to overcome amount, solubility and bioavailability limitations.
The formulations that are usually employed to test the effect of acetogenin from An-
nona cherimola on cell lines are mainly obtained with the use of organic solvents. Dimethyl
sulphoxide is the most employed solvent in these tests, being applied either as co-solvent
(1%) with water or as single solvent. Annonacin and molvizarin, obtained through this
single solvent formulation, have been tested for larvicidal [56], anti-protist (leishmanicidal
and trypanocidal) [61] and different insecticidal activities, such as oviposition capacity [13].
Apart from that, kidney studies with VERO cells have also been carried out on acetogenins
combined with rollisniastatin-2 and on squamocin, where pure a DMSO solution was
mixed with cell cultures [61,62]. Methanol and ethanol solutions have also been employed
to test acetogenin obtained from Annona cherimola. Its insecticidal activity against mosquito
and different lepidoptera larvae were assayed by He and co-workers [48]. Tolosa et al. [55]
employed methanol to solve motrilin, rolliniastatin-2, bullatacin and annonacin. Mclaugh-
lin’s research team [63,64] used ethanol solutions and the same acetogenins plus aromin-A
to evaluate their effects on lung, breast and colon tumor cell lines. Hidalgo et al. [65] con-
ducted a number of bioassays against lepidoptera larvae, where other lesser known Annona
cherimola acetogenins, such as almunequin, cherimolin-1, cherimolin-2 and squamocin
were tested, and acetone was used as an alternative solvent.
Notwithstanding the good results achieved by solving the acetogenins in organic sol-
vents, this method is not feasible for further objectives, such as their application to human
assays, since their inoculation while mixed in pure ethanol or DMSO is not an acceptable
approach. This is one of the reasons why some authors have focused on alternative formu-
lae that intend to compensate poor water solubility. In short, two methods mainly based
on encapsulation techniques have been devised to improve the performance of Annona
cherimola acetogenins. The first one uses polymeric compounds to produce core/shell struc-
tures that mask the lower physicochemical properties of the lactones. Polyethylene glycol
(PEG) with certain modifications is the most commonly used polymeric compound, but
also a monomethoxy derivative (mPEG), ε-caprolactone (PCL), poly (lactide-co-glycolide)
(PLGA) or cholesterol (Chol) have also been tested. These polymeric nanoparticles (NPs)
have been successfully tested for the treatment of different types of breast cancer. For in-
stance, Wang’s group tested the effect of bullatacin encapsulated in PCL-PEG nanoparticles
against a 4T1 cancer cell line as well as in vivo breast tumor-bearing mice. They obtained
a high percentage of 20–60 nm-size encapsulated NPs (>70%) which demonstrated twice
the ability to reduce tumor volume than free bullatacin [66]. In a patented expansion
of their study, the same authors applied their encapsulation method to squamocin and
applied the formula to HeLa cell lines and ex vivo HeLa tumor-bearing mice. Tumor
volume was thereby reduced by 64.11%, in comparison to the 43.1% reduction achieved
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by free squamocin. This novel method exhibited up to 144 h of controlled release of the
drug [67]. A similar method has been patented by Ao et al. to apply the use of polymeric
nanoparticles to cherimolin and motrilin for oral administration instead of being injected
through the mice tail vein [68].
The same authors have also patented a method to modify the different polymers
that had been previously assayed so that they would include different stabilizers, such as
albumin serum or soybean lecithin, in the nanoparticle suspension. This new method was
employed to encapsulate bullatacin, but they exhibited a shorter delivery time (controlled
release for 96 h) compared to when just the polymer nanoparticles were administered.
Nevertheless, this method seems to improve the antitumor efficacy of bullatacin against
liver tumor, with a maximum inhibition rate of 74.8% in the tumor volume [69]. The size of
the nanoparticles used in this method was similar to that of nanoparticles which had not
been added a stabilizer, which means that these co-polymers did not affect the chemical
structure layout [70].
In a different line of investigation, micelles based on pseudorotaxanes with cyclodex-
trins (CDs) are becoming a prominent approach for the encapsulation of Annona cherimola
acetogenins. Wang’s working group has used supramolecular polymer micelles (SMPMs)
with β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) to encapsulate bul-
latacin (Figure 4). One of the methods used employed folic acid as the guest molecule to
be hosted in the cyclodextrin toroid, which would act as a building-block for the micelle,
while another method employed soybean lecithin, a really standardized guest molecule
in SMPMs science [71,72]. The nanostructures generated with the cyclodextrin molecules
seem to be bigger than the particles synthesized using polymers, with sizes between
140 and 200 nm. In addition, the encapsulation percentages are also lower, with values
between 45% and 60%. Despite these apparently worse results, this method allows for the
incorporation of oligoelements, thanks to which it presents the advantage of serving a dou-
ble purpose: anti-tumoral agent and nutraceutical supplier. In the case of the β-CD/folic
acid micelles, the structure includes vitamin B9, which facilitates bio-recognition and target-
ing towards the liver. Besides from everything mentioned above, natural CDs are chemical
compounds approved as a food additive by the EU since 2018, which supports their use as
an excipient instead of other substances [73]. With respect to the inhibition of 4T1 tumors
volume, there are no significant differences between the two methods, when compared
against polymeric nanoparticles, with inhibition values at around 70%. It should be noted
that drug release times change drastically as the micelles’ composition changes. In the
case of the β-CD/folic acid, the drug release times are quite similar to those of polymeric
nanoparticles, with 142 h required for the total delivery of the drug [74]. On the other hand,
HP-β-CD/Lecithin presents an 80 h release profile [75]. The currently published papers do
not cast any light over this behavior, but it could be attributed to the higher solubility of
HP-β-CD in water when compared to that of β-CD. This improved solubility of the micelles
in the media would facilitate their degradation. A similar method has been patented by
Hong et al., where SMPMs are synthesized by means of three natural cyclodextrins (α, β
and γ) that act as guests for different molecular weight polyethylene-glycol units ranging
from 600 to 2000. No specific values have been reported on encapsulation percentages,
although over 50% has been claimed. It should also be noted that bullatacin release time is
limited to 72 h. When the different methods are applied to the same acetogenin and their
data (Table 3) are compared, as in case of bullatacin, it seems that the guest molecule in the
SMPMs building-block is crucial with respect to core release times, and their increment in
molecular weight/molecular volume reduce the drug delivery time.
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β-CD/Folic Acid Bullatacin 142 58 441.14 [74]
HP-β-
CD/Lecithin Bullatacin 80 46 643.90 [75]
β-CD/PEG Bullatacin 72 50 600.00–2000.00 [76]
α-CD/Urea Annonacin 33 35 60.02 [20]
Gutiérr z et l. employed SMPMs based on α-CD and urea to encapsulate annonacin.
In line with other tudies, cytot xicity to liver cells was the main objective, and it was
proven t at annonacin is sele tive to tumor cells, with over 87% of cell survival hen
the acetogenin is applied to non-tumor l liver cells (HEK-293) [20]. In this case, although
both the encapsulation percentage and the drug delivery time provided the lowest val es,
it should be highlighted that annonacin is completely different from other previously
encapsulated and tested acetogenins, since it presents a mono-THF structure instead of the
bis-THF structure of bullatacin. No studies on the subject have been found to allow the
comparison between these two methods.
Most of the formulation cases have focused on bullatacin, the most abundant aceto-
genin, but it should be emphasized that the authors used an acetogenin enrichment fraction
and based their studies on determining bullatacin content, since it is the main compound in
the fraction. However, an efficient encapsulation procedure for single acetogenins should
be developed, similarly to the one previously described for anonacin, so that any antitu-
moral efficacy can be attributed to the only compound in the media and not to the possible
synergistic effect that the different mixtures of acetogenins may exhibit.
6. Annona Cherimola Mill. Acetogenin Derivatives
From the moment acetogenins were discovered, many researchers have tried to syn-
thesize mimics or analogous structures with a similar bioactivity profile but with a less
complicated production process at laboratory scale. Attending to isolation yields, most
authors reported values between 0.00019% and 0.003% [20,26], which poses a limit on
the prospective practical usage of the acetogenins found in Annona cherimola. Naturally,
different methods have been implemented to try and increase the yields obtained from the
synthesis of acetogenins. One of such methods consists of modifying their THF core by
incorporating a different functional group or structure that would facilitate the synthesis
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process. Miyoshi’s research team replaced the bis-THF core in bullatacin with either an
ether group or a tetrahydroxyl core. For the first strategy, a 1,2-dimethoxyciclopentane
derivative was used as the central unit, while for the second approach, a hexane-tetraol
unit was employed. Both approaches were tested against NADH oxidase inhibition, but
neither of them surpassed the activity level exhibited by bullatacin [77]. The dimethoxi-
ciclopentane acetogenin mimic achieved comparable values (IC50 = 1.0 nM) with regard
to bullatacine (IC50 = 0.83 nM) [78]. Nevertheless, the tetraol structure and the MOM
protecting derivative are far from the expected values, with 20 nM and 4100 nM of IC50,
respectively. Rodier et al. [79] employed a similar approach using linear ether groups to
substitute the bis-THF core and obtain a bullatacinone mimic. In this case, it was tested
against L1210 leukemia cells. The dimethoxiheptane acetogenin mimic achieved simi-
lar IC50 values to those of natural bullatacinone, which, considering the lower number
of steps that are required for its synthesis, make this mimic a prominent candidate for
further studies.
Following the same approach as described above for lineal ethers, Yu et al have recently
synthesized at gram-scale a new and interesting derivative, based on bullatacin (Figure 5),
known as AA005, [80]. This Annona cherimola acetogenin mimic has been tested against
human colon carcinoma cell line SW620 in vivo, and against different human cancer cell
lines in vitro [81]. In the case of colon cancer, the anticancer effect goes through the down
regulation of myeloid cell leukemia-1 protein, which is usually overexpressed or amplified
in human cancer, which suggests its critical role in tumor cell survival [82]. Furthermore,
according to the fluorescent images obtained from AA005-fluorescein derivatives that were
administered into any of the hydroxyl positions [83], the AA005 compound presented
a different distribution in healthy human cells compared to the accumulations on the
mitochondria that only took place in cancerous cells.
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ration of an aryloxy group at the end of the chain instead of γ-butyrolactone, something 
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using pure bullatacin, but with the advantage of improved water solubility [87]. Sugars 
have been recently introduced as a replacement of the hydroxyl groups in squamocin and 
bullatacin. Glucose or galactose units have been employed to generated acetogenin 
mimics with different substitution degrees. Among the derivatives synthesized, 
mono-galactosylated squamocin exhibited 1.37 mg/mL water solubility, while pure 
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The same bullatacin mimic synthesis method has been used to incorporate more
carbon-spacing units between the oxygen-ether atoms that are found in the core, but no
higher inhibition values against ovarian cancer (KB), liver cancer (BEL-7402) or colon cancer
cell lines (HT-29 and HCT-8) were expressed [84]. Based on these results, we can conclude
that the core composition in Annona cherimola acetogenin mimics is highly relevant for an
efficient inhibitory capacity.
Following this line of investigation consisting of acetogenin core modification, Gould
et al. synthesized a squamocin mimic. However, the original squamocin molecule was
drastically denatured, since it had its characteristic γ-butyrolactone final ring and the
ether groups removed. The most remarkable point in the mimic structure produced by
Gould is the tetrahidropyrane core connected to the triazole ring, that replaces the bis-
THF of squamocin [85]. Similar approaches were implemented by Ichimaru et al., where
bullatacin mimics were synthesized employing piperazine core. However, the studies on
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competitive inhibition showed that the core modification led to a different mechanism
of action, even though the mitochondrial complex I remained the target [86]. One of the
interesting novelties in the synthesis method described above is the incorporation of an
aryloxy group at the end of the chain instead of γ-butyrolactone, something that had been
previously tested on both sides of the chain by the same research group, which synthesized
a bullatacin mimic structure without relevant results with regard to the inhibition of the
mitochondrial complex I [87]. On the other hand, the introduction of biotin instead of
aryloxy groups exhibited comparable IC50 inhibition values of the same mitochondrial
complex, with 3.9 nM of the mimic versus 1.8 nM of the actual bullatacin [88].
Sugar residues have also been employed to replace THF segments, and Bachan et al.
demonstrated that these bullatacin mimics present similar mechanism of action to real
bullatacin when tested against HeLa, breast cancer (MDA-MB231), leukemia (Jurkat) and
prostate cell lines (PC-3). Each one of the carbohydrate units tested were α-mannose
derivatives with their hydroxyl groups replaced at different degrees. The units tested
are presented in Figure 6. The bioactivity results are comparable to those obtained when
using pure bullatacin, but with the advantage of improved water solubility [87]. Sugars
have been recently introduced as a replacement of the hydroxyl groups in squamocin
and bullatacin. Glucose or galactose units have been employed to generated acetogenin
mimics with different substitution degrees. Among the derivatives synthesized, mono-
galactosylated squamocin exhibited 1.37 mg/mL water solubility, while pure squamocin is
totally insoluble in water.




Figure 6. Carbohydrate precursors employed in the synthesis of Annona cherimola acetogenin mimics and 
mono-galactosylated squamocin. 
Delving into the substitution of the γ-butyrolactone ring, Yabunaka and co-workers 
confirmed that the replacement of this group by an ubiquinone ring does not affect the 
inhibitory action of acetogenin. Inspired by previous experiences with bullatacin, they 
modified the chain end group by incorporating an ubiquinone ring that displayed the 
same inhibitory activity against mitochondrial complex I as the acetogenin original mol-
ecule [88,89]. 
In those cases, where the hydroxyl groups were replaced, similarly to in the previ-
ously mentioned experiments with sugars, the formation of acetyl and methoxymethyl 
(MOM) groups in squamocin, molvizarin, and motrilin was tested, but none of them ex-
hibited an increment in their bioactivity when their insecticidal properties were assessed 
against the Spodoptera frugiperda larvae that infect corn and cotton crops [65]. On the 
other hand, the work developed by Shi et al. achieved more remarkable results when 
adding biotin units to squamocin and bullatacin to form acyl groups plus a spacer, in-
stead of the hydroxyl groups. Bis-biotynilated squamocin with an ε-aminocapric acid 
spacer achieves better inhibition results against breast and mastocytoma cancer cell lines 
(4T1 and P815, respectively), if compared to those obtained when using pure bullatacin 
or squamocin. The synthesis of the bis-biotynilated squamocin can be completed in just 
two steps, but yields are quite low, in the order of between 1% and 20% [90]. 
We could conclude that the addition of biologically relevant structures (sugars or 
biotins) to Annona cherimola acetogenins through the functionalization of their hydroxyl 
group is a really good option to achieve an improved bioactivity. Even more remarkable 
is the enhancement of the physicochemical properties of acetogenins when certain car-
bohydrates are added. Unfortunately, this step requires the previous isolation of aceto-
genin, which poses a considerably limiting factor that could be overcome by imple-
menting acetogenin mimics. Among such acetogenin mimics, AA005 stands out because 
it can be synthesized at gram-scale and also for having demonstrated its anticancer effect 
through in vivo studies. 
7. Summary and Perspectives 
Annonaceous acetogenins (ACGs) are one of the most interesting plant-derived 
natural compounds. They constitute a unique class of C35 or C37 secondary metabolites 
derived from the polyketide pathway. Since the first report on the bioactivity of uvaricin 
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excellent bioactivity in the P-388 lymphocytic leukemia system in mice, these natural 
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el i g i t t e s stit tio f t - t r l ct e ri ,
c fir ed that the replacement of this group by an ubiqui one ring does not affect
the inhibitory action of ac togenin. Inspired by previous experiences with bullatacin,
they modifi d the chain end group by incorporati g an biquino e ring that displayed
the same inhibitory activity against mitochondrial complex I as the acetogenin original
mol cule [88,89].
I t se c ses, here the hydroxyl groups were replaced, similarly to in the previously
mentioned experiments with sugars, the formation of acetyl and methoxymethyl (MOM)
groups in squamocin, molvizarin, and motrilin was tested, but none of them exhibited an
increment in their bioactivity when their insecticidal properties were assessed against the
Spodoptera frugiperda larvae that infect corn and cotton crops [65]. On the other hand, the
work developed by Shi et al. achieved more remarkable results when adding biotin units to
squamocin and bullatacin to form acyl groups plus a spacer, instead of the hydroxyl groups.
Bis-biotynilated squamocin with an ε-aminocapric acid spacer achieves better inhibition
results against breast and mastocytoma cancer cell lines (4T1 and P815, respectively), if
compared to those obtained when using pure bullatacin or squamocin. The synthesis of
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the bis-biotynilated squamocin can be completed in just two steps, but yields are quite low,
in the order of between 1% and 20% [90].
We could conclude that the addition of biologically relevant structures (sugars or
biotins) to Annona cherimola acetogenins through the functionalization of their hydroxyl
group is a really good option to achieve an improved bioactivity. Even more remarkable is
the enhancement of the physicochemical properties of acetogenins when certain carbohy-
drates are added. Unfortunately, this step requires the previous isolation of acetogenin,
which poses a considerably limiting factor that could be overcome by implementing ace-
togenin mimics. Among such acetogenin mimics, AA005 stands out because it can be
synthesized at gram-scale and also for having demonstrated its anticancer effect through
in vivo studies.
7. Summary and Perspectives
Annonaceous acetogenins (ACGs) are one of the most interesting plant-derived natural
compounds. They constitute a unique class of C35 or C37 secondary metabolites derived
from the polyketide pathway. Since the first report on the bioactivity of uvaricin in 1982,
isolated from the roots of Uvaria accuminata Oliv. by Jolad et al., which exhibited excellent
bioactivity in the P-388 lymphocytic leukemia system in mice, these natural products
have been extensively investigated. Moreover, they are recognized as one of the most
powerful groups of complex inhibitors. These metabolites have shown a wide spectrum of
biological activities, with particular reference to their anticarcinogenic properties. It has
been demonstrated that certain variations in their backbone, including their THF system,
the type of terminal lactone group, the number and position of their hydroxyl groups and
their stereochemistry are crucial factors that influence their biological activity. It has been
generally confirmed by most studies that ACGs containing adjacent bis-THF (T-C) and α,β-
unsaturated methyl γ-lactone (L-A) ring were more active than those with non-adjacent
groups or with the β-hydroxyl methyl γ-lactone group (L-C) [15]. However, further studies
on the correlation between their structure and their activity are needed in order to clearly
determine this association between structural requirements and biological activity.
Recent studies have further delved into novel formulation methods, other than the
usual co-solvent, to be successfully applied to ACGs. Among them, two methods have
gathered special attention, namely, polymeric nanoparticles (NPs) and micelle synthesis
(SMPMs). Both of them have rendered promising results regarding the modulation of
ACGs delivery, their stability and their water solubility.
Given that Annona cherimola Mill acetogenins are generally found in low concentration
mixtures, a deeper knowledge on such structural requirements should lead to the desired
development of new synthetic derivatives and more efficient drugs. In this line, a number
of studies have focused on the synthesis of mimics and derivatives, but none of these has
surpassed the cytotoxic and antitumor profiles already exhibited by the natural single
compounds. Nevertheless, AA005, a mimic of bullatacin, has stood out because of the
possibility of synthesizing it at gram-scale and also for its good in vivo results; two factors
that make it a promising compound. Furthermore, the modification of natural acetogenin
to incorporate sugar units seems to open the way to increasing the solubility of these
compounds in water, while conveniently enhancing some of its physicochemical properties.
Despite the ancient and popular consumption of the fresh fruit and other food products
derived from these plants, further studies would be required to determine safe consumption
doses as well as to develop an efficient isolation and administration methodology that
allows for the benefit of an efficient medical use of their recognized bioactivity.
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